SG3 Management’s Pfizer PFE Stock Holding History

SG3 Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-135,000	Closed	-$7.97M	–	1276
2021 Q4	$7.97M	Buy	+135,000	New	+$6.69M	0.16%	114
2020 Q4	–	Sell	-42,160	Closed	-$1.47M	–	1175
2020 Q3	$1.47M	Buy	+42,160	New	+$1.48M	0.05%	334
2017 Q3	–	Sell	-5,270	Closed	-$168K	–	235
2017 Q2	$168K	Buy	+5,270	New	+$166K	0.04%	186

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

SG3 Management's PFE Position: Q1 2022 in Review

SG3 Management sold out of Pfizer (PFE) in Q1 2022, closing a stake of 135,000 shares — an estimated $7.97M sold.

SG3 Management first reported a position in PFE in Q2 2017 and held it in 3 quarters. The position peaked at $7.97M in Q4 2021. 3,195 funds tracked by Wall St. Rank hold PFE as of Q1 2022.

SG3 Management reported no remaining Pfizer position as of Q1 2022 after selling out during the quarter.
SG3 Management sold 135,000 Pfizer shares in Q1 2022, an estimated $7.97M.
SG3 Management first reported a position in Pfizer in Q2 2017 and held it in 3 quarters.
SG3 Management's Pfizer position peaked at $7.97M in Q4 2021.
3,195 funds tracked by Wall St. Rank held Pfizer as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.